Análisis de costo-efectividad de ranibizumab comparado con implante intravítreo de dexametasona, triamcinolona, aflibercept y bevacizumab, para pacientes el tratamiento de pacientes con edema macular secundario a oclusión de la vena central de la retina (OVCR) en Colombia

Rodríguez Guio, Oscar; Moreno Vizcaya, Mabel; Andrea Cañón, Lorena; Vanegas Escamilla, Egdda Patricia; Rodríguez, Francisco J; Baquero, Roberto.
Bogotá; IETS; mayo 2016. 53 p. tab, ilus, graf.
Monografia em Espanhol | BRISA, LILACS | ID: biblio-846624

Documentos relacionados

  1. THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion.
  2. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
  3. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
  4. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
  5. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
  6. Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center.
  7. Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema.
  8. Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use.
  9. Fund Black scientists.
  10. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.